Tags

Type your tag names separated by a space and hit enter

Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
Mini Rev Med Chem. 2016; 16(4):272-89.MR

Abstract

Imidazole derivatives have known to possess a diverse range of pharmacological activity. In particular, one of ruthenium-based derivatives, imidazolium [trans-RuCl4(1H-imidazole)(DMSOS)] (NAMI-A) which is now in clinical trials, opens a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. This mini-review overviews some representative examples of imidazole-containing ruthenium complexes (ICRCs) with in vitro anticancer activities. Special attention is paid on ICRCs with the activities more potent than Cisplatin, and their correlation with their DNA binding properties in the context of possible cancer chemotherapeutic applications. The ICRCs are divided into two main categories according to their dark and light activated cytotoxicity; the former case is further clarified into mononuclear complexes including tris(bidentate polypyridyl) ruthenium complexes and those containing monodentatively coordinative imidazole ligands as well as polynuclear complexes. The perspective, challenges and future efforts for investigations into ICRCs are pointed out or suggested.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableBeijing Key Laboratory of Energy Conversion and Storage Materials, and the Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P.R. China. kzwang@bnu.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26586123

Citation

Liu, Ping, et al. "Recent Advances On Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes." Mini Reviews in Medicinal Chemistry, vol. 16, no. 4, 2016, pp. 272-89.
Liu P, Jia J, Zhao Y, et al. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes. Mini Rev Med Chem. 2016;16(4):272-89.
Liu, P., Jia, J., Zhao, Y., & Wang, K. Z. (2016). Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes. Mini Reviews in Medicinal Chemistry, 16(4), 272-89.
Liu P, et al. Recent Advances On Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes. Mini Rev Med Chem. 2016;16(4):272-89. PubMed PMID: 26586123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes. AU - Liu,Ping, AU - Jia,Jia, AU - Zhao,Yue, AU - Wang,Ke-Zhi, PY - 2015/03/30/received PY - 2015/07/22/revised PY - 2015/11/17/accepted PY - 2015/11/21/entrez PY - 2015/11/21/pubmed PY - 2016/10/26/medline SP - 272 EP - 89 JF - Mini reviews in medicinal chemistry JO - Mini Rev Med Chem VL - 16 IS - 4 N2 - Imidazole derivatives have known to possess a diverse range of pharmacological activity. In particular, one of ruthenium-based derivatives, imidazolium [trans-RuCl4(1H-imidazole)(DMSOS)] (NAMI-A) which is now in clinical trials, opens a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. This mini-review overviews some representative examples of imidazole-containing ruthenium complexes (ICRCs) with in vitro anticancer activities. Special attention is paid on ICRCs with the activities more potent than Cisplatin, and their correlation with their DNA binding properties in the context of possible cancer chemotherapeutic applications. The ICRCs are divided into two main categories according to their dark and light activated cytotoxicity; the former case is further clarified into mononuclear complexes including tris(bidentate polypyridyl) ruthenium complexes and those containing monodentatively coordinative imidazole ligands as well as polynuclear complexes. The perspective, challenges and future efforts for investigations into ICRCs are pointed out or suggested. SN - 1875-5607 UR - https://www.unboundmedicine.com/medline/citation/26586123/Recent_Advances_on_Dark_and_Light_Activated_Cytotoxity_of_Imidazole_Containing_Ruthenium_Complexes_ L2 - http://www.eurekaselect.com/137150/article DB - PRIME DP - Unbound Medicine ER -